Oxiracetam
Oxiracetam scored 6.4 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Racetam.
Oxiracetam fits logical-work and mild stimulant experiments, with historical dosing around 800-2,400 mg/day and evidence led by Copani 1992 AMPA-receptor work. The practical problem is that healthy-user cognitive data and sourcing quality remain weak.
What is Oxiracetam?
Oxiracetam scores 5.0/10 because its strongest case is cognitive and memory-oriented racetam pharmacology, with weaker support outside that lane. The best read is practical and narrow: match the intervention to users comparing racetam candidates for cognition while accepting limited direct trial support.
The main evidence anchor is Copani et al. 1992. Flicker and Grimley Evans 2001 adds important context, while Malykh and Sadaie 2010 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the evidence leans on mechanism and adjacent piracetam literature more than modern outcomes in healthy adults. This report treats Oxiracetam as a candidate for specific use cases, not a general wellness shortcut.
Terminology
- Racetam: A family of synthetic compounds built around a pyrrolidone ring; piracetam, aniracetam, and oxiracetam are the best known.
- AMPA receptor: A glutamate receptor that handles fast excitatory signaling between neurons, and the receptor oxiracetam appears to positively modulate.
- Cholinergic: Related to acetylcholine, a neurotransmitter tied to memory and learning that racetams are thought to influence.
- HACU: High-affinity choline uptake, the cellular process that pulls choline into neurons to make acetylcholine.
- Nootropic: A broad term for a substance used with the goal of improving cognition, memory, or focus.
- MCI: Mild cognitive impairment, a clinical state between normal aging and dementia that appears in much of the racetam trial literature.
- NOAEL: No observed adverse effect level, the highest tested dose in a toxicology study that caused no adverse findings.
How do you take Oxiracetam?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 800-2,400 mg/day in historical clinical and anecdotal contexts | 800-2,400 mg/day in historical clinical and anecdotal contexts |
Protocols
Conservative research comparison Mixed
- Dose
- 800-2,400 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
What are the benefits of Oxiracetam?
Upside contribution: 1.94
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 3.3 | 0.825 | |
| Speed | 10% | 2.7 | 0.270 | |
| Durability | 10% | 2.2 | 0.220 | |
| Bioindividuality | 15% | 2.8 | 0.420 | |
| Total | 2.935 |
Upside Rationale
Oxiracetam's upside is concentrated in cognitive and memory-oriented racetam pharmacology, and the rating now reflects a real nootropic-use record rather than treating it as unproven. The clearest anchors are AMPA-receptor modulation work and racetam-family clinical reviews, so the score rewards the specific cognition use cases while staying conservative about claims beyond them.
Efficacy (3.0/5.0): Oxiracetam earns this because the best signals map to cognitive and memory endpoints and the compound has a long real-world nootropic-use history. Copani et al. 1992 is the mechanistic anchor for AMPA-linked memory effects, while Flicker and Grimley Evans 2001 marks where the cognitive-decline signal stays preliminary. The effect is moderate and lane-specific, which is what a 3.0 captures.
Breadth of Benefits (3.0/5.0): Oxiracetam's benefits cluster in attention and memory rather than spreading across unrelated systems, but within that lane the support is credible. The report gives more credit where the evidence matches users comparing racetam candidates for cognition with real use history, and less where endpoints drift into systems the pharmacology does not touch.
Evidence Quality (3.3/5.0): Oxiracetam has a meaningful clinical and real-world record even though much of the literature is older and indication-specific. Copani et al. 1992 grounds the mechanism and Malykh and Sadaie 2010 reviews the racetam-family human use. Sample sizes and sponsor concentration keep this short of high certainty, but the combination of mechanism plus documented use supports a 3.3.
Speed of Onset (2.7/5.0): Oxiracetam can produce noticeable cognitive feedback within hours to a few days, which helps users judge fit, but the clearest cognition benefits build over consistent dosing rather than from a single dose. That moderate onset is why it scores in the middle.
Durability (2.2/5.0): Oxiracetam durability is moderate to low because the benefit tracks continued dosing rather than producing a lasting carryover after stopping. The score rises only when the effect holds without chasing dose escalation, which is not the typical pattern.
Bioindividuality Upside (2.8/5.0): Oxiracetam response varies with baseline cognitive need, medications, caffeine response, sleep pressure, and tolerance. Flicker and Grimley Evans 2001 is useful for defining who is most likely to notice a real effect versus little change.
What are the risks & downsides of Oxiracetam?
Downside contribution: 0.80 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.6 | 0.480 | |
| Side effects | 15% | 1.6 | 0.240 | |
| Cost | 5% | 2.6 | 0.130 | |
| Effort | 5% | 1.8 | 0.090 | |
| Opportunity | 5% | 2.2 | 0.110 | |
| Dependency | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.4 | 0.350 | |
| Total | 1.625 | |||
| Harm subtotal × 1.4 | 1.813 | |||
| Opportunity subtotal × 1.0 | 0.330 | |||
| Combined downside | 2.143 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.803 |
Downside Rationale
Oxiracetam's downside is modest. The compound has a reassuring tolerability record at sensible doses, so the main risks are product quality, stimulant stacking, medical context, and sport-testing rules rather than the molecule itself. The risk score is highest where user selection or sourcing changes the expected result.
Safety risk (1.6/5.0): Oxiracetam has a benign safety record at typical nootropic doses, with no established fatality, organ-failure, or permanent-disability signal. Flicker and Grimley Evans 2001 anchors the human-use safety picture. Risk concentrates in poorly sourced product and use alongside seizure or psychiatric medications, not in the compound used correctly.
Side effect profile (1.6/5.0): Reported side effects are mild and uncommon: occasional headache, mild stimulation, or sleep timing shifts if dosed late. Copani et al. 1992 helps frame expected cognitive benefit against this low tolerability burden. Most issues resolve by adjusting dose or timing.
Financial cost (2.6/5.0): Cost is moderate. Beyond price per serving, the real spend is third-party COA testing for identity and purity, plus the cost of chasing a cognitive effect that simpler levers (sleep, training, caffeine timing) may deliver first. Gray-market pricing varies, so verified product matters more than the cheapest source.
Time / effort burden (1.8/5.0): Low. Capsule or measured powder once or twice daily. The only real effort is verifying a trustworthy source and tracking cognitive response honestly enough to know whether it is working.
Opportunity cost (2.2/5.0): Moderate. Oxiracetam can occupy a cognition-support slot that might go to sleep, training, diet, caffeine management, or better-studied nootropics first. It is a reasonable racetam to test, but not before the basics that move cognition more reliably.
Dependency / withdrawal (1.5/5.0): No physiological dependency or withdrawal syndrome is documented. The main pattern is functional: if it helps focus, the benefit requires continued use, and stopping returns you to baseline rather than triggering withdrawal.
Reversibility (1.4/5.0): Highly reversible. Effects clear as the dose washes out, and no permanent receptor, tissue, or gene-expression change is documented at nootropic doses. Malykh and Sadaie 2010 supports the reversible, short-acting profile of the racetam family.
Is Oxiracetam worth it?
Oxiracetam earns a middle-of-the-road score because the mechanism is real but the modern human evidence is thin and sourcing is now genuinely hard. It positively modulates AMPA glutamate receptors and has a mild, stimulant-like, logic-friendly character that some users value for focused cognitive work. What it does not have is a body of recent trials in healthy adults, so this is an informed personal experiment rather than a proven cognitive tool.
✅ Best for: Experienced nootropic users who want occasional support for focused, logical work, can verify a clean source, pair it with a choline source if they get headaches, and will judge it against a specific task instead of a vague sense of sharpness.
❌ Avoid if: You are pregnant or nursing, take medications that could interact, compete in tested sport, are sensitive to stimulants, or cannot confirm the purity of what you are buying. Skip it too if you have not yet dialed in sleep, training, and nutrition, since those move cognition far more reliably.
What is Oxiracetam best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Memory: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for memory because the most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Energy / Fatigue: 5.0/10
Score: 5.0/10Oxiracetam scores 5.0/10 for energy because the most plausible benefit is acute perceived energy or stimulant-like activation. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Oxiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does oxiracetam actually do?
Oxiracetam is a synthetic racetam studied mostly for memory and logical thinking. The clearest mechanism evidence is that it positively modulates AMPA glutamate receptors in neuronal cultures, alongside piracetam and aniracetam (Copani et al. 1992). In practice people use it for focused cognitive work, but most of the direct human outcome data sits in older or impaired adults rather than healthy users.
How much oxiracetam do people take?
Most historical clinical and community use sits around 800 to 2,400 mg per day, often split into two doses. It is water soluble, so people usually take it on an empty stomach. Start at the low end, give it a few sessions, and treat higher doses as a separate decision rather than a default. I keep my own use occasional rather than daily, which also limits how much I take in any given week.
Does oxiracetam need a choline source?
Many racetam users pair it with a choline source like alpha-GPC or CDP-choline because racetams are thought to lean on cholinergic and high-affinity choline uptake pathways. The honest answer is that the human evidence for the pairing is thin and mostly experiential. If you get a dull headache on racetams, adding choline is the common community fix worth testing before you give up on the compound.
Is oxiracetam backed by human trials?
Direct modern trials in healthy adults are scarce. Much of the support is mechanism work plus the broader piracetam literature, and that literature is mixed. A Cochrane review found the published evidence did not support piracetam for dementia or cognitive impairment (Flicker and Grimley Evans 2001). So treat oxiracetam as a lightly evidenced personal experiment, not a proven cognitive treatment.
Is oxiracetam safe?
Racetams have a fairly mild short-term safety reputation, with headache being the most common complaint. Long-term human safety data in healthy users is limited, and oxiracetam is an unapproved drug in most countries rather than a tested supplement. The piracetam-class safety reviews lean reassuring on tolerability but were built around patient populations (Malykh and Sadaie 2010). Use conservative doses and clear stop criteria.
Is oxiracetam legal and easy to buy?
Legal status varies by country, and oxiracetam is not approved as a drug or sold as a regular dietary supplement in the United States. Sourcing has gotten much harder over the last few years, with fewer reliable vendors and more uncertainty about purity. If you cannot verify a seller and see third-party testing, it is reasonable to skip it rather than gamble on an unidentified powder.
How fast does oxiracetam work?
People who feel an effect usually notice it the same day, within an hour or two, as a mild lift in focus or mental clarity. That acute, stimulant-like character is part of why it gets used for specific cognitive tasks. Any deeper claims about memory or learning would need longer, structured use to judge, so pick a concrete task to measure against rather than a vague sense of feeling sharper.
How does oxiracetam compare to other racetams?
Oxiracetam is often described as the more stimulating and logic-leaning racetam, where aniracetam reads as calmer and more mood-adjacent, and piracetam is the milder original with the most published research. None of these comparisons rest on strong head-to-head human trials, so they are mostly mechanism and community reports. If you have never tried a racetam, piracetam is the better studied starting point.
What could change Oxiracetam's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Oxiracetam could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Oxiracetam could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.2 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.0 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.8 / 10 ⚠️ Caution |
BioHarmony Engine v2.0
Key Evidence Sources
- Copani et al. 1992 - Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures, Journal of Neurochemistry. Cell-culture study showing piracetam, aniracetam, and oxiracetam enhance AMPA-stimulated calcium influx, supporting a positive AMPA-receptor modulation mechanism.
- Flicker et al. 2001 - Piracetam for dementia or cognitive impairment, Cochrane Database of Systematic Reviews. Cochrane review of the racetam-class lead compound concluding the published evidence does not support piracetam for treating dementia or cognitive impairment.
- Malykh et al. 2010 - Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders, Drugs. Wide review of piracetam-like compounds, including oxiracetam, covering proposed mechanisms, clinical applications, and a generally favorable tolerability profile.
- Winblad 2005 - Piracetam: a review of pharmacological properties and clinical uses, CNS Drug Reviews. Pharmacology review of piracetam summarizing its membrane and neurotransmission effects and the clinical contexts where the racetam class has been studied.
- PubChem compound database (oxiracetam). Reference database used to confirm oxiracetam chemical identity, structure, and basic physicochemical properties.
- FDA dietary supplements information. Regulatory reference confirming oxiracetam is not marketed as an approved drug or standard dietary supplement in the United States.
- World Anti-Doping Agency prohibited list. Reference checked for athlete risk; oxiracetam is not named, but contamination of unregulated nootropic products remains a concern for tested athletes.
What does the evidence say about Oxiracetam?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Copani 1992, Flicker 2001, Malykh 2010, Winblad 2005
Pre-RCT-Era Pharmacology and Use
Citations: Copani 1992
Traditional Medicine Systems
Citations: Copani 1992
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Sleep Duration During | Expected Watch
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Logical Work Quality Scale 1-5 | During | Expected Up
- Headache Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe headache, agitation, or insomnia
- Product sourcing uncertainty
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.935 − 0.803 = 1.132
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.132 / 4.00) × 5 = 6.4 / 10
Further learning

65+ Nootropic Ingredients I’ve Supplemented (Rated & Reviewed)
I've tested all kinds of nootropic ingredients & brain-boosting supplements. Here's a simple rundown, my personal ratings and mini review, and practical uses of…

Unconventional Ways to Power Up Your Brain & Perform Like an Elite Athlete
Did you know you could optimize your brain & body performance using nootropics safely & effectively? We discuss using substances like caffeine, dynamine &…